- immunodeficiency disease after transplantation with thymic epithelium. Lancet 1976, II, 1270-1272.
- 154. Ferrari S, Grande A, Manfredini R, et al. Expression of interleukins 1, 3, 6, stem cell factor and their receptors in acute leukemia blast cells and in normal peripheral lymphocytes and monocytes. Eur J Haematol 1993, 50, 141-148.
- Young DC, Griffin JD. Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood 1986, 68, 1178-1181.
- 156. Bradbury D, Zhu YM, Hunter AE, Russell NH. Acute myeloblastic leukemia cells with autonomous growth express high levels of bcl-2 protein which is regulated by autocrine growth factors. *Blood* 1993, 82 (10 Suppl 1), 124a (abstract 480).
- Zhu YM, Bradbury D, Russel NH. Both exogenous and autocrine GM-CSF suppress apoptosis in the blast cells of acute myeloblastic leukemia. *Blood* 1993, 82 (10 Suppl 1), 236a (abstract 931).
- 158. Ellingsworth LR, Brennan JE, Fok K, et al. Antibodies to the terminal portion of cartilage-inducing factor A and transforming growth factor β. J Biol Chem 1986, 261, 12362–12367.
- 159. Gatherer D, Dijke P ten, Baird DT, Akhurst RJ. Expression of TGFβ isoforms during first trimester human embryogenesis. Development 1990, 110, 445-460.
- Schmid P, Cox D, Bilbe G, Maier R, McMaster GK. Differential expression of TGFβ1, β2, β3 genes during mouse embryogenesis. Development 1991, 111, 117-130.
- Barnard JA, Lyons RM, Moses HL. The cell biology of transforming growth factor β. Biochem Biophys Acta 1990, 1032, 79-87.

- Hatzfeld J. Control of G<sub>0</sub>. phase of human bone marrow cells. Sem Hemat 1992, 29, 2-6.
- 163. Tessier N, Hoang T. Transforming growth factor β inhibits the proliferation of the blast cells of acute myeloblastic leukemia. Blood 1988, 72, 159–164.
- 164. Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. *Blood* 1992, 80, 1750-1757.
- 165. Lin JK, Chou CK. In vitro apoptosis in the human hepatoma cell line induced by transforming growth factor β1. Cancer Res 1992, 52, 385–388.
- 166. Oberhammer F, Fritsch G, Pavelka M, et al. Induction of apoptosis in cultured hepatocytes and in the regressing liver by transforming growth factor β1 occurs without activation of an endonuclease. Toxicol Lett 1992, 64/65, 701-704.
- 167. Taetle R, Payne C, Dos Santos B, Russell M, Segarini P. Effects of transforming growth factor β1 on growth and apoptosis of human acute myelogenous leukemia cells. Cancer Res 1993, 53, 3386-3393.
- Pierce JH, Ruggierd M, Fleming TP, et al. Signal transduction through the EGF receptor transfected in IL-3 dependent hematopoietic cells. Science 1988, 239, 628-630.

## News

### 18th Symposium of Clinical Hyperthermia

This symposium will be held on 21-24 May 1995 in Kiev, Ukraine. It is being organised by the International Clinical Hyperthermia Society. For further information contact Prof. Sergej P. Osinski, R.E. Kavetski Institute for Oncology Problems Acad. of Sci. of the UkrSSR, 45 Vasilkovskaja Str, Kiev 22, Ukraine. Tel. 117 044 266 9802; Fax 044 271 7329.

## Critical issues in tumour microcirculation, angiogenesis and metastasis: biological significance and clinical relevance

This workshop, a continuing education course of the Harvard Medical School (HMS) and Massachusetts General Hospital (MGH), Boston, Massachusetts, U.S.A., will be held between 5 and 9 June 1995. Topics include tumour angiogenesis, tumour

stroma generation, metastasis, tumour blood flow, tumour micro-environment, adhesion molecules, leucocyte-endothelial interactions and delivery of novel and conventional agents. For further information contact Norman Shostak, Department of Continuing Education, 641 Huntington Ave, Boston, Massachusetts 02115, U.S.A. Tel. 617 432 0196; Fax 617 432 1562.

#### **Drug Resistance in Cancer**

An international symposium, which will include sessions on clinical, molecular and pharmacological aspects of drug resistance, will be held in Dublin, Ireland between the 20 and 24 September 1995. For more information, please contact Professor Martin Clynes, National Cell & Tissue Culture Centre/Bioresearch Ireland, Dublin City University, Dublin 9, Ireland. Tel. 01 704 5700; Fax: 01 704 5484.



# 1995 FORTHCOMING EDUCATIONAL EVENTS

20th - 24th March

Advanced Course in collaboration with the EORTC

Venue: Bruges, Belgium

Leukaemias: New Developments

Chairpersons: R. Willemze (Leiden), R. Zittoun (Paris)

27th - 30th March

Advanced Course Venue: Cambridge, U.K.

Introduction to Molecular Biology for Clinicians

Chairpersons: M. Bronchud (Barcelona), K. Sikora (London)

26th - 28th April

Advanced Course Venue: E.I.O., Milan, Italy

Colorectal Cancer

Chairpersons: T. Cooke (Glasgow), P. Boyle (E.I.O.),

B. Andreoni (E.I.O.)

19th - 20th June

Advanced Course Venue: Milan, Italy

Imaging of Lymphnodes in Oncology

and Staging of Tumours

Chairpersons: S. Wallace (New York), D. Allison (London),

M. Bellomi (E.I.O.)

3rd - 5th July

Advanced Course in collaboration with the EORTC

Venue: Brussels, Belgium

**Economic Evaluations in Cancer Care** 

Chairpersons: C. Williams (Southampton), K. Torfs (Brussels)

14th - 16th September

Advanced Course Venue: E.I.O., Milan, Italy

Medical Oncology

Chairpersons: F. Cavalli (Bellinzona), M. Aapro (E.I.O.)

25th - 29th September

Advanced Course in collaboration with the EORTC

Venue: Bruges, Belgium

**Cancer Clinical Trials** 

Chairpersons: S. Marsoni (Milan), J. Houghton (London),

C. Arrigo (Brussels), M. Parmar (Cambridge)

2nd - 4th October

Advanced Course Venue: E.I.O., Milan, Italy

**Breast Cancer** 

Chairpersons: U. Veronesi (E.I.O.), J. Petit (E.I.O.)

11th - 14th October

Advanced Course Venue: E.I.O., Milan, Italy

**Gynaecological Oncology** 

Chairpersons: S. Pecorelli (E.I.O.), J. Vermorken (Amsterdam),

N. Einhorn (Stockholm)

13th - 16th November

Advanced Course Venue: E.I.O., Milan, Italy

**Chest Tumours** 

Chairpersons: P. Goldstraw (London), P. Bunn (Denver),

M. Mezzetti (E.I.O.)

27th November - 1st December

Advanced Course in collaboration with the EORTC

Venue: Leuven, Belgium

**Data Management in Cancer Clinical Trials** 

Chairpersons: E. McFadden (Boston), D. Riley (London),

K. Vantongelen (Leuven)

For further information, please contact: European School of Oncology, Via Ripamonti 66 20141 Milan, Italy Tel: (39-2)57305416 Fax: 57307143